Matthew J Durand1, Natalya S Zinkevich1, Michael Riedel1, David D Gutterman1, Victoria L Nasci1, Valerie K Salato1, John B Hijjawi1, Charles F Reuben1, Paula E North1, Andreas M Beyer2. 1. From the Department of Physical Medicine and Rehabilitation (M.J.D.), Department of Medicine, Cardiovascular Center (M.J.D., N.S.Z., M.R., D.D.G., V.L.N., A.M.B.), Department of Pathology, Division of Pediatric Pathology (V.K.S., P.E.N.), Department of Plastic Surgery (J.B.H.), Department of Cardiothoracic Surgery (C.F.R.), and Department of Physiology (A.M.B.), Medical College of Wisconsin, Milwaukee; and Department of Health and Medicine, Carroll University, Waukesha, WI (N.S.Z.). 2. From the Department of Physical Medicine and Rehabilitation (M.J.D.), Department of Medicine, Cardiovascular Center (M.J.D., N.S.Z., M.R., D.D.G., V.L.N., A.M.B.), Department of Pathology, Division of Pediatric Pathology (V.K.S., P.E.N.), Department of Plastic Surgery (J.B.H.), Department of Cardiothoracic Surgery (C.F.R.), and Department of Physiology (A.M.B.), Medical College of Wisconsin, Milwaukee; and Department of Health and Medicine, Carroll University, Waukesha, WI (N.S.Z.). abeyer@mcw.edu.
Abstract
OBJECTIVE: This study examined vascular actions of angiotensin 1-7 (ANG 1-7) in human atrial and adipose arterioles. APPROACH AND RESULTS: The endothelium-derived hyperpolarizing factor of flow-mediated dilation (FMD) switches from antiproliferative nitric oxide (NO) to proatherosclerotic hydrogen peroxide in arterioles from humans with coronary artery disease (CAD). Given the known vasoprotective properties of ANG 1-7, we tested the hypothesis that overnight ANG 1-7 treatment restores the NO component of FMD in arterioles from patients with CAD. Endothelial telomerase activity is essential for preserving the NO component of vasodilation in the human microcirculation; thus, we also tested whether telomerase activity was necessary for ANG 1-7-mediated vasoprotection by treating separate arterioles with ANG 1-7±the telomerase inhibitor 2-[[(2E)-3-(2-naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid. ANG 1-7 dilated arterioles from patients without CAD, whereas dilation was significantly reduced in arterioles from patients with CAD. In atrial arterioles from patients with CAD incubated with ANG 1-7 overnight, the NO synthase inhibitor NG-nitro-l-arginine methyl ester abolished FMD, whereas the hydrogen peroxide scavenger polyethylene glycol catalase had no effect. Conversely, in vessels incubated with ANG 1-7+2-[[(2E)-3-(2-naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid, NG-nitro-l-arginine methyl ester had no effect on FMD, but polyethylene glycol catalase abolished dilation. In cultured human coronary artery endothelial cells, ANG 1-7 significantly increased telomerase activity. These results indicate that ANG 1-7 dilates human microvessels, and dilation is abrogated in the presence of CAD. Furthermore, ANG 1-7 treatment is sufficient to restore the NO component of FMD in arterioles from patients with CAD in a telomerase-dependent manner. CONCLUSIONS: ANG 1-7 exerts vasoprotection in the human microvasculature via modulation of telomerase activity.
OBJECTIVE: This study examined vascular actions of angiotensin 1-7 (ANG 1-7) in human atrial and adipose arterioles. APPROACH AND RESULTS: The endothelium-derived hyperpolarizing factor of flow-mediated dilation (FMD) switches from antiproliferative nitric oxide (NO) to proatherosclerotic hydrogen peroxide in arterioles from humans with coronary artery disease (CAD). Given the known vasoprotective properties of ANG 1-7, we tested the hypothesis that overnight ANG 1-7 treatment restores the NO component of FMD in arterioles from patients with CAD. Endothelial telomerase activity is essential for preserving the NO component of vasodilation in the human microcirculation; thus, we also tested whether telomerase activity was necessary for ANG 1-7-mediated vasoprotection by treating separate arterioles with ANG 1-7±the telomerase inhibitor 2-[[(2E)-3-(2-naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid. ANG 1-7 dilated arterioles from patients without CAD, whereas dilation was significantly reduced in arterioles from patients with CAD. In atrial arterioles from patients with CAD incubated with ANG 1-7 overnight, the NO synthase inhibitor NG-nitro-l-arginine methyl ester abolished FMD, whereas the hydrogen peroxide scavenger polyethylene glycolcatalase had no effect. Conversely, in vessels incubated with ANG 1-7+2-[[(2E)-3-(2-naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid, NG-nitro-l-arginine methyl ester had no effect on FMD, but polyethylene glycolcatalase abolished dilation. In cultured human coronary artery endothelial cells, ANG 1-7 significantly increased telomerase activity. These results indicate that ANG 1-7 dilates human microvessels, and dilation is abrogated in the presence of CAD. Furthermore, ANG 1-7 treatment is sufficient to restore the NO component of FMD in arterioles from patients with CAD in a telomerase-dependent manner. CONCLUSIONS:ANG 1-7 exerts vasoprotection in the human microvasculature via modulation of telomerase activity.
Authors: Gursev S Dhaunsi; Mariam H M Yousif; Saghir Akhtar; Mark C Chappell; Debra I Diz; Ibrahim F Benter Journal: Eur J Pharmacol Date: 2010-05-04 Impact factor: 4.432
Authors: K Damm; U Hemmann; P Garin-Chesa; N Hauel; I Kauffmann; H Priepke; C Niestroj; C Daiber; B Enenkel; B Guilliard; I Lauritsch; E Müller; E Pascolo; G Sauter; M Pantic; U M Martens; C Wenz; J Lingner; N Kraut; W J Rettig; A Schnapp Journal: EMBO J Date: 2001-12-17 Impact factor: 11.598
Authors: E Paxinou; M Weisse; Q Chen; J M Souza; C Hertkorn; M Selak; E Daikhin; M Yudkoff; G Sowa; W C Sessa; H Ischiropoulos Journal: Proc Natl Acad Sci U S A Date: 2001-09-18 Impact factor: 11.205
Authors: Hiroto Miura; John J Bosnjak; Gang Ning; Takashi Saito; Mamoru Miura; David D Gutterman Journal: Circ Res Date: 2003-02-07 Impact factor: 17.367
Authors: Andrew M South; Hossam A Shaltout; Lisa K Washburn; Alexa S Hendricks; Debra I Diz; Mark C Chappell Journal: Clin Sci (Lond) Date: 2019-01-08 Impact factor: 6.124
Authors: Kathleen M Lukaszewicz; Matthew J Durand; Jessica R C Priestley; James R Schmidt; L Adrienne Allen; Aron M Geurts; Julian H Lombard Journal: J Vis Exp Date: 2017-12-05 Impact factor: 1.355
Authors: Dawid S Chabowski; Andrew O Kadlec; Karima Ait-Aissa; Joseph C Hockenberry; Paul J Pearson; Andreas M Beyer; David D Gutterman Journal: Br J Pharmacol Date: 2018-10-11 Impact factor: 8.739
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Samara Silva de Moura; Adália Táci Pereira Mendes; Francisco de Assis Dias Martins-Júnior; Nádia Lúcia Totou; Daniel Barbosa Coelho; Emerson Cruz de Oliveira; Daisy Motta-Santos; Robson Augusto Souza Dos Santos; Lenice Kappes Becker Journal: BMC Sports Sci Med Rehabil Date: 2021-05-06
Authors: Matthew J Durand; Shelby N Hader; Alexa Derayunan; Natalya Zinkevich; Jennifer J McIntosh; Andreas M Beyer Journal: Microcirculation Date: 2020-09-05 Impact factor: 2.628